MUSCLELABS TESTOVIRON 150 mg/ml

FORMULA:

Each 1 ml. contains:

PROPERTIES:

Testosterone is a sex hormone that is produced naturally in men and women. This medicine is used to treat illnesses caused by low levels of the hormone testosterone in the body. These conditions include delayed puberty, impotence and other hormonal imbalances.

INDICATIONS:

Testosterone replacement therapy in male hypogonadism when testosterone deficiency has been confirmed using clinical data and biochemical tests.

TESTOSTERONE DOSIS

- Testosterone replacement therapy in male hypogonadism:

DOSIS:

- Recommended dosage: two doses of the gel pump (that is, 40.5 mg of testosterone) applied once a day at approximately the same time, preferably during the morning. TESTOSTERONE ADMINISTRATION METHOD

- Administer on an area of intact, clean and dry skin. You must gently rub it with your finger until the skin dries; The continuation must cover the application area, preferably with hung clothing. Luego you must wash your hands with water and soap.

PRECAUTIONS AND WARNINGS:

Before starting testosterone therapy, exclude the risk of pre-existing prostate cancer. At least once a year, carry out periodic monitoring of the mammary glands and prostate according to recommended methods (rectal examination and serum PSA estimation) in patients receiving treatment with testosterone. It will be carried out every year on elderly patients and other high-risk patients (those with clinical or familial factors). I want to accelerate the development of subclinical prostate cancer or benign prostatic hyperplasia. Cardiovascular, renal or hepatic disorders, epilepsy, migraine, diabetes mellitus, with a predisposition to developing edema (severe heart, hepatic or renal failure or ischemic heart disease) from treatment. with androgens you can increase sodium and water retention; In case of serious complications caused by the presence of edema, interrupt the treatment. ETA. Coagulation disorders, thrombophilia or risk factors for venous thromboembolism (VTE), taking into account post-commercialization reports and studies of thrombotic events (e.g., deep vein thrombosis, pulmonary embolism, ocular thrombosis) during testosterone treatment in these patients. In thrombophilic patients, cases of VTE have been reported following anticoagulant treatment, which is why continuation of testosterone treatment after the first thrombotic event must be carefully evaluated. If treatment continues, additional measures should be taken to minimize the individual risk of VTE. Epilepsy or migraine. In people with hypogonadism there is a risk of sweat apnea, especially in those with risk factors such as obesity or illnesses, chronic lung disease. Periodically check hemoglobin, hematocrit, liver function tests and lipid profile, as well as basal testosterone levels. Children < 18 years old. Risk of azoospermia. Patients with cancer and risk of hypercalcemia (and associated hypercalciuria) due to bone metastases (regular control of serum Ca). The topical gel also: can be transferred to another person through close skin-to-skin contact at any time after dosing and cause an increase in serum testosterone concentrations and possible adverse reactions (e.g., increase in facial or body skin, appearance of the voice, irregularities of the menstrual cycle in women and premature puberty and growth of genitals in children) in case of repeated contacts (accidental androgenization). In case of virilization, testosterone treatment must be immediately suspended until the cause is identified. This transfer can be avoided by wearing clothing that covers the area of application or douching before contact. Frequent doses can cause symptoms of slow remission, as this is a long-acting medication. It is recommended to suspend the medication immediately.

TESTOSTERONE INTERACTIONS

- With androgen treatments it is possible to observe a change in insulin sensitivity, glucose tolerance, glycemic control and glucosylated hemoglobin levels. In diabetic patients it may be necessary to reduce antidiabetic medication. The concomitant administration of testosterone with ACTH or corticosteroids may favor the formation of edema. Be careful with liver or heart disease, or with a predisposition to edema. Increase the activity of: oral anticoagulants derived from coumarins. Laboratory: decrease the level of thyroxinebinding dlobulin.

EL EMBARAZO:

Estesterone induces virilizing effects in female fetuses when administered to embarassed women. Animal studies have demonstrated reproductive toxicity. A relationship has been revealed between treatment with androgens and certain forms of cancer. Data obtained in female rats indicate an increase in the incidence of prostate cancer after treatment with testosterone. Although sexual hormones promote the development of certain tumors induced by known carcinogens, the clinical relevance of this observation is unknown. Several studies on rodents and primates have demonstrated that testosterone treatment can affect fertility, reducing spermatogenesis in proportion to the dose administered. It has been demonstrated that testosterone has a virilizing effect on rat fetuses (increased anogenital distance) when administered subcutaneously. In doses of 0.5 or 1 mg/day (as propionate ester) to rats pregnant for organogenesis.

TESTOSTERONE ADVERSE REACTIONS

Polycythemia, increase in hematocrit, increase in erythrocyte count, increase in hemoglobin; weight gain; Sophocos; acne; increase in prostate specific antigen, abnormal prostate exam, benign prostatic hyperplasia; reactions at the place of injection. Cutaneous route: entothal symptoms (mood changes, affective upheavals, anger, aggression, impatience, insomnia, abnormal sweating, increased libido); skin reactions (acne, alopecia, dry skin, skin lesions, contact dermatitis, hair color changes, skin eruption, hypersensitivity at the application site, stinging at the application site, increase in PSA, hematocrit and hemoglobin.

IN BOX CONTAINS:

Bottle with 10mL content

Store at a temperature below 25°C in a dry and out of reach of children.